LIVERO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,482 JPY | -7.72% |
|
-6.44% | +44.44% |
| 2023 | Livero Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2023 | Tranche Update on Livero Inc.'s Equity Buyback Plan announced on February 20, 2023. | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an expected P/E ratio at 40.71 and 22.76 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Sector: Real Estate Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +44.44% | 49.64M | - | ||
| -3.08% | 27.21B | B+ | ||
| +5.49% | 20.81B | C- | ||
| -26.30% | 9.97B | C- | ||
| -18.04% | 9.67B | B- | ||
| +3.70% | 9.31B | B+ | ||
| -4.03% | 6.78B | C- | ||
| -6.97% | 5.73B | B+ | ||
| +47.78% | 4.83B | - | - | |
| -2.31% | 2.42B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
-
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 9245 Stock
- Ratings Livero Inc.